Clinical efficacy of melittin in the treatment of cats infec ted with the feline immunodeficiency virus

Summary

Objective: The bee venom melittin shows an antiviral efficacy against the human immunodeficiency virus in cell culture. It was shown to be non-toxic for cats. Aim of this pilot study was to investigate the clinical efficacy and side-effects of melittin in cats naturally infected with feline immunodeficiency virus (FIV). Material and methods: The study was performed as a prospective, placebo-controlled double-blinded trial. Twenty cats were included, of which 10 cats each were treated with either melittin (500 μg/kg body weight) or phosphate-buffered saline (placebo) subcutaneously twice per week. During the treatment period of 6 weeks, the cats’ general health status, determined by the Karnofsky’s score, and the severity of clinical signs (conjunctivitis and stomatitis) using a clinical scoring system were evaluated. Haematology, biochemistry profiles, lymphocyte subpopulations, CD4/CD8 ratio, and pterines (biopterine, 7-xanthopterine) as surrogate parameters were also compared. Results: The general health status and the clinical scores for conjunctivitis and stomatitis improved in cats treated with melittin. A statistically significant improvement however could only be detected for conjunctivitis in cats treated with melittin compared to cats treated with placebo which was likely due to different scores between both groups at the beginning. No influence on the lymphocyte subpopulations, CD4/CD8 ratio, and pterine concentrations was observed. No side effects occurred in this study. Conclusion and clinical relevance: In the protocol used in the present study, no significant efficacy of melittin could be detected. However, efficacy of melittin, especially if applied in a higher dosage as in the present study or for a longer period, could be evaluated in further studies. Synergistic effects if used in combination with classic antiretroviral drugs could be an interesting future approach.

Keywords

FIV - bee venom - conjunctivitis - stomatitis - lymphocyte subpopulation - therapy

• Literatur

• 1 Ackley CD, Yamamoto JK, Levy N, Pedersen NC, Cooper MD. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol 1990; 64: 5652-5655.
• 2 Albiol Matanic VC, Castilla V. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int J Antimicrob Agents 2004; 23: 382-389.
• 3 Ammentorp-Schmidt B. Antiretrovirale Wirkung von Melittin bei der Rauscher-Leukämie-Infektion in vivo und in vitro. Dissertation. Ludwig-Maximilians-Universität München; 1994
• 4 Bazzo R, Tappin MJ, Pastore A, Harvey TS, Carver JA, Campbell ID. The structure of melittin. A 1H-NMR study in methanol. Eur J Biochem 1988; 173: 139-146.
• 5 Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O’Keefe BR, Mori T, Gulakowski RJ, Wu L. et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997; 41: 1521-1530.
• 6 Buckheit RW, White EL, Fliakas-Boltz V, Russell J, Stup TL, Kinjerski TL, Osterling MC, Weigand A. et al. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother 1999; 43: 1827-1834.
• 7 De Clercq E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev 2000; 20: 323-349.
• 8 Dey B, Lerner DL, Lusso P, Boyd MR, Elder JH, Berger EA. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 2000; 74: 4562-4569.
• 9 Dunn JD, Killion JJ. Melittin-evoked increase in plasma corticosterone levels. Life Sci 1988; 43: 335-343.
• 10 Egberink HF, Lutz H, Horzinek MC. Use of western blot and radioimmunoprecipitation for diagnosis of feline leukemia and feline immunodeficiency virus infections. J Am Vet Med Assoc 1991; 199: 1339-1342.
• 11 Esser AF, Bartholomew RM, Jensen FC, Müller-Eberhard HJ. Disassembly of viral membranes by complement independent of channel formation. Proc Natl Acad Sci USA 1979; 76: 5843-5847.
• 12 Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322: 166-172.
• 13 Goldberg M, Gassner F, Singer L, Merkenschlager M. Pteridinkonzentrationen in Harn und Organgeweben von Hund und Katze bei verschiedenen Neoplasien und Virusinfektionen. Tierarztl Prax 1989; 5 Suppl. 37-41.
• 14 Habermann E, Jentsch J. Sequence analysis of melittin from tryptic and peptic degradation products. Hoppe Seylers Z Physiol Chem 1967; 348: 37-50.
• 15 Hartmann A, Wilhelm N, Balzarini J, Hartmann K. Clinical efficacy of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine (PMPDAP) in the treatment of feline immunodeficiency virus-infected cats. J Feline Med Surg 2012; 14: 107-112.
• 16 Hartmann K. Entwicklung eines Testsystems zur Erprobung neuer Medikamente gegen die FIV-Infektion der Katze als Modell für die Behandlung erworbener Immunschwächesyndrome. Habilitation. Ludwig-Maximilians-Universität München; 1995
• 17 Hartmann K, Donath A, Beer B, Egberink HF, Horzinek MC, Lutz H, Hoffmann-Fezer G, Thum I. et al. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol 1992; 35: 167-175.
• 18 Hartmann K, Ferk G, North T, Pedersen N. Toxicity associated with high dosage 9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine therapy off attempts to abort early FIV infection. Antiviral Res 1997; 36: 11-25.
• 19 Hartmann K, Kuffer M. Karnofsky’s score modified for cats. Eur J Med Res 1998; 3: 95-98.
• 20 Hartmann K, Kuffer M, Balzarini J, Naesens L, Goldberg M, Erfle V, Goebel F, De Clercq E. et al. Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 120-128.
• 21 Hoffmann-Fezer G, Thum I, Ackley C, Mysliwietz J, Hartmann K, Kraft W. T-lymphocyte subpopulations in FIV-positive and -negative cats. Schweiz Arch Tierheilkd 1990; 132: 438.
• 22 Hofmann-Lehmann R, Holznagel E, Ossent P, Lutz H. Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: hematology, clinical chemistry, and lymphocyte subsets. Clin Diagn Lab Immunol 1997; 4: 33-42.
• 23 Hood J, Jallouk A, Campbell N, Ratner L, Wickline S. Cytolytic nanoparticles attenuate HIV-1 infectivity. Antivir Ther 2003; 18: 95-103.
• 24 Kashman Y, Gustafson KR, Fuller RW, Cardellina JH, McMahon JB, Currens MJ, Buckheit RW, Hughes SH. et al. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem 1992; 35: 2735-2743.
• 25 Marcos JF, Beachy RN, Houghten RA, Blondelle SE, Pérez-Payá E. Inhibition of a plant virus infection by analogs of melittin. Proc Natl Acad Sci USA 1995; 92: 12466-12469.
• 26 Mori T, Boyd MR. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob Agents Chemother 2001; 45: 664-672.
• 27 Novotney C, English RV, Housman J, Davidson MG, Nasisse MP, Jeng CR, Davis WC, Tompkins MB. Lymphocyte population changes in cats naturally infected with feline immunodeficiency virus. AIDS 1990; 4: 1213-1218.
• 28 Patil AD, Freyer AJ, Eggleston DS, Haltiwanger RC, Bean MF, Taylor PB, Caranfa MJ, Breen AL. et al. The inophyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the Malaysian tree, Calophyllum inophyllum Linn. J Med Chem 1993; 36: 4131-4138.
• 29 Rauer M. Nachweis und Quantifizierung des Felinen Immundefizienz-Virus in natürlich infizierten Katzen mit Hilfe der Polymerase-Kettenreaktion. Dissertation. Ludwig-Maximilians-Universität München; 1993
• 30 Reddy MM, McKinley GF, Grieco MH. Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2’,3‘-dideoxyinosine (ddI). J Clin Lab Anal 1991; 5: 396-398.
• 31 Sherer R, Dutta B, Anderson R, Laudette-Aboulhab J, Kamarulzaman A, D’Amico R, Paton N, Abdullah MS. A phase IB study of (+)-calanolide A in HIV-1-infected, antiretroviral therapy-naive patients. Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections. 30 January-2 February 2000. San Francisco, USA: 171.
• 32 Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989; 2: 114-124.
• 33 Tosteson MT, Tosteson DC. The sting. Melittin forms channels in lipid bilayers. Biophys J 1981; 36: 109-116.
• 34 Wachinger M. Wirkungen von Melittin auf die HIV-1-Produktion in vitro.. Ebenhausen: Langewiesche-Brandt; 1994
• 35 Wachinger M, Kleinschmidt A, Winder D, Von Pechmann N, Ludvigsen A, Neumann M, Holle R, Salmons B. et al. Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J Gen Virol 1998; 79: 731-740.
• 36 Wachinger M, Ludvigsen A, Neumann M, Brack-Werner R, Saermark T, Erfle V. Amphipathic peptide melittin: inhibitory effects on HIV-LTR activity, HIV-RNA levels and HIV protein expression. Proceedings of the IX. International AIDS Conference. 7-11 June 1993. Berlin, Germany: 146.
• 37 Wachinger M, Saermark T, Erfle V. Influence of amphipathic peptides on the HIV-1 production in persistently infected T lymphoma cells. FEBS Lett 1992; 309: 235-241.
• 38 Walker C, Canfield PJ, Love DN, McNeil DR. A longitudinal study of lymphocyte subsets in a cohort of cats naturally-infected with feline immunodeficiency virus. Aust Vet J 1996; 73: 218-224.